Influence of tiotropium bromide (TB) on mucociliary clearance (MCC) in patients with COPD Source: Annual Congress 2009 - Healthcare and treatment of COPD Year: 2009
Influence of tiotropium bromide (TB) and carbocysteine (C) on mucociliary clearance (MCC) in patients with COPD Source: Annual Congress 2012 - COPD treatment and varia Year: 2012
Evaluation of mucociliary clearance‘s (MCC) condition in patients with COPD. Influence of tiotropium bromide (TB) on MCC Source: Annual Congress 2007 - Treatment of COPD Year: 2007
Laboratory investigation of sputum and mucociliary clearance (MCC) condition in patients with COPD Source: Annual Congress 2011 - Bronchial hyperresponsiveness and exhaled and sputum biomarkers Year: 2011
Effects of β2 agonists on mucociliary clearance (MCC) in patients with asthma - association to polymorphisms of the β2-adrenoceptor Source: Eur Respir J 2003; 22: Suppl. 45, 478s Year: 2003
Comparison of fluticasone propionate + salmeterol (FP+S) and montelukast (MK) on bronchial reactivity (BR), pulmonary function (PF) and clinical outcome in children with mild asthma Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009
Pharmacokinetics (PK) and safety of budesonide plus formoterol (BF) (320/9mcg) Spiromax® and BF (400/12mcg) Turbuhaler® following two inhalations (+/– charcoal [char] block) in healthy volunteers (HV) Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013
Pharmacokinetics (PK) and safety of budesonide plus formoterol (BF) (160/4.5mcg) Spiromax® and BF (200/6mcg) Turbuhaler® following two inhalations (+/– charcoal [char] block) in healthy volunteers (HV) Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders Year: 2013
Pharmacodynamics (PD) of low and high strength budesonide plus formoterol (BF) Spiromax® and BF Turbuhaler® in healthy volunteers (HV) Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
Mucociliary clearance and regular exercise: Responses of the nasal mucociliary transport of subjects with COPD Source: International Congress 2015 – Latest insights into pulmonary rehabilitation Year: 2015
Integrated analyses of phase II safety data support the safety of glycopyrrolate-formoterol fumarate (GFF) MDI (PT003) and glycopyrrolate (GP) MDI (PT001) in COPD Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013
Local and system effects of tiotropium bromide (TB) Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD Year: 2010
Mucociliary clearance (MCC) in the trachea in mild-moderate COPD occurs in spirals Source: International Congress 2015 – Pathophysiological mechanisms at different scales: lung, airways, muscles and symptom perception Year: 2015
Indacaterol/glycopyrronium (IND/GLY) improves lung function, health status and rescue medication use vs salmeterol/fluticasone (SFC) independent of symptom response: The FLAME study Source: International Congress 2017 – Clinical challenges in chronic lung diseases Year: 2017
Inhalation characteristics with Spiromax® (S) versus Turbuhaler® (T) dry powder inhalers (DPI) in healthy adults (HA) and in patients with asthma (A) or COPD Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders Year: 2013
COPD: Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination and oxygen saturation (OS) in patients (pts) with different plasma surfactant protein D (SP-D) level Source: International Congress 2015 – COPD: notable points Year: 2015
LATE-BREAKING ABSTRACT: TRINITY: A phase III study to compare the efficacy and safety of an extrafine triple combination of beclometasone dipropionate (BDP), formoterol fumarate (FF), and glycopyrronium bromide (GB) pMDI (CHF5993) with tiotropium (Tio) and a free triple combination of BDP/FF (Foster®) + Tio in COPD patients Source: International Congress 2016 – Late-breaking topics in airways disease Year: 2016
Impairment of mucociliary clearance in COPD and smokers: Same or different? Source: Annual Congress 2012 - Tobacco dependence and respiratory disease Year: 2012
Comparative evaluation on the synergism of roflumilast (RFL) and glycopyrronium (Gly) vs ciclesonide (CLS) and Gly on lung volumes and exercise tolerance in severe COPD Source: International Congress 2015 – Clinical exercise physiology in health and disease Year: 2015
Mucociliary clearance (MCC) disorders in patient with acute bronchitis (AB) and acute exacerbation (AE) of COPD and ways of it correction Source: Annual Congress 2009 - Drug effects in COPD Year: 2009